AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19056555
Drug: Bar with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar with 0.9 g beta-glucan
Trial: 18158075
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 µg BID
Trial: 18158075
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine QD (titrated targeting FSG < or =5.6 mmol/L)
Trial: 15079179
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (1 mg/kg)
Trial: 15079179
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (2 mg)
Trial: 15079179
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral and nebulized)
Trial: 11586485
Drug: gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil 600 mg twice daily for 4 months
Trial: 11586485
Drug: simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 10 mg daily for 4 months
Trial: 11586485
Drug: gemfibrozil and
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gemfibrozil and simvastatin (both treatments)
Trial: 11586485
Drug: simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin treatment
Trial: 9884813
Drug: dyed aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dyed aqueous nasal spray
Trial: 9884813
Drug: vigorous inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vigorous inhalation while spraying
Trial: 913863
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxprenolol every six hours during marathon bowling
Trial: 913863
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg oxprenolol 60 minutes prior to shooting matches
Trial: 27612487
Drug: Individual feedback
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report
Trial: 27612487
Drug: Partner feedback
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partner feedback group (n = 54) that received an alarm and a weekly feedback report shared with a friend, family member, or peer
Trial: 27612487
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 36) that received a pill‐monitoring device with no alarms or feedback
Trial: 23135345
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg/day with vitamin D
Trial: 21596994
Drug: Pregabalin 200
RxNorm normalized name: pregabalin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 200 mg
Trial: 9291170
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg daily for 2 days administered every 4 weeks for 24 weeks
Trial: 3092099
Drug: Naltrexone hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone hydrochloride (Trexan) at 300 mg dosage
Trial: 9000837
Drug: Capsules (A)
RxNorm normalized name: Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules (A)
Trial: 9000837
Drug: Tablets (C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (C)
Trial: 23261129
Drug: Aripiprazole adjunctive
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole adjunctive to lithium/valproate
Trial: 23261129
Drug: Aripiprazole adjunctive
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole adjunctive to lamotrigine
Trial: 23261129
Drug: Aripiprazole adjunctive
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole adjunctive to mood stabilizers
Trial: 23261129
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood stabilizer monotherapy
Trial: 11408333
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation in a temporal forced choice paradigm
Trial: 25006070
Drug: Ractopamine hydrochloride
RxNorm normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ractopamine hydrochloride (RAC; 5 mg/kg)
Trial: 22437659
Drug: Arthroscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic treatment followed by exercise therapy for 2 months
Trial: 20552353
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using Photofrin, HPD, ALA, or Foscan
Trial: 20552353
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) for laryngeal cancers
Trial: 20552353
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) compared to conventional therapies
Trial: 16325020
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined regimen: combined oestrogen/progestogen skin patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day)
Trial: 16325020
Drug: Interrupted regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted regimen: oestrogen-only patches (releasing 80 microg estradiol/day) for 4 days followed by combined oestrogen/progestogen patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day) for 3 days
Trial: 2050424
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg three times daily)
Trial: 2050424
Drug: Trimethoprim-sulfamethoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (960 mg three times daily)
Trial: 27862066
Drug: AFXL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFXL treatment
Trial: 26399603
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical therapy for the first 4 weeks
Trial: 22730470
Drug: Lesogaberan 60
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 60 mg twice daily
Trial: 22730470
Drug: Lesogaberan 120
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 120 mg twice daily
Trial: 22730470
Drug: Lesogaberan 180
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 180 mg twice daily
Trial: 22730470
Drug: Lesogaberan 240
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 240 mg twice daily
Trial: 16737869
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (EM) 10 mg/kg every 6 hours for 2 days, followed by 4 mg/kg every 6 hours for another 5 days
Trial: 11444418
Drug: Enteric-coated garlic
RxNorm normalized name: GARLIC OIL TAB,EC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated garlic powder tablets with 9.6 mg allicin-releasing potential
Trial: 9120818
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension without sodium lauryl sulfate (SLS)
Trial: 9120818
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension with sodium lauryl sulfate (SLS)
Trial: 9120818
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil tablet formulation
Trial: 31962179
Drug: Pre-ICU cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ICU cold intravenous (i.v.) fluids
Trial: 31962179
Drug: No pre-ICU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-ICU cold intravenous (i.v.) fluids
Trial: 23343363
Drug: Client-centred occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centred occupational therapy (OT)
Trial: 18158312
Drug: Gelatin solution
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin solution
Trial: 18158312
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution
Trial: 14521738
Drug: Diltiazem infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem infusion (0.1 mg/kg/h)
Trial: 9407509
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lisinopril (group 1)
Trial: 9407509
Drug: No ACE
RxNorm normalized name: Amino Acetic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACE inhibitor therapy (group 2)
Trial: 2862808
Drug: Atracurium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 2.5 mg
Trial: 2862808
Drug: Atracurium 5
RxNorm normalized name: cisatracurium 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 5 mg
Trial: 2862808
Drug: Fazadinium 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium 3.75 mg
Trial: 29321141
Drug: Multidisciplinary, aerobic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (MIRT) for 4 weeks
Trial: 25378424
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of autologous bone marrow mononuclear stem cells (BMSCs)
Trial: 17651149
Drug: Symptomatic steroid-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic steroid-free asthmatics
Trial: 16092896
Drug: Experiential cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential cognitive therapy (ExCT), 4 sessions
Trial: 16092896
Drug: Experiential cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential cognitive therapy (ExCT)
Trial: 12005142
Drug: Brånemark System
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark System implants
Trial: 2194004
Drug: Iopanoic acid
RxNorm normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopanoic acid (1 gm daily for 21 days)
Trial: 28740376
Drug: FP/FORM 500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FORM 500/20 µg
Trial: 28740376
Drug: FP/FORM 250/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FORM 250/10 µg
Trial: 28740376
Drug: FP/FORM 500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FORM 500/20 µg and FP/FORM 250/10 µg
Trial: 28740376
Drug: FP/FORM 500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FORM 500/20 µg, FP/FORM 250/10 µg, FORM
Trial: 23386653
Drug: Prednisolone (PRED)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (PRED) 7.5 mg once daily (n = 12)
Trial: 23386653
Drug: Prednisolone (PRED)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (PRED) 30 mg once daily (n = 12)
Trial: 19710500
Drug: laromustine and
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: laromustine and high-dose cytarabine (HDAC)
Trial: 19710500
Drug: high-dose cytarabine/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose cytarabine/placebo
Trial: 17240287
Drug: 800 mcg
RxNorm normalized name: Biotin 800 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mcg daily oral folic acid
Trial: 15566917
Drug: Fluid balance
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid balance and volume administered on postoperative day 2
Trial: 18621791
Drug: Bimatoprost once
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost once daily
Trial: 12488264
Drug: Bimatoprost twice
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost twice daily
Trial: 496555
Drug: Drug-free state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free state serum calcium levels in patients with EPS
Trial: 496555
Drug: Drug-free state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free state serum magnesium levels in patients with EPS
Trial: 496555
Drug: Neuroleptic dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic dosage
Trial: 496555
Drug: Serum calcium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum calcium and magnesium levels during neuroleptic treatment
Trial: 31897708
Drug: NAPP application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAPP application into the pockets, adjunctive to NSPT
Trial: 21882343
Drug: treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with anti-miR-21
Trial: 19122476
Drug: HX575 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HX575 (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Trial: 19122476
Drug: Comparator epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator epoetin alfa (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Trial: 17525168
Drug: Fosaprepitant 115
RxNorm normalized name: fosaprepitant 115 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 115 mg
Trial: 17525168
Drug: Fosaprepitant up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant up to 150 mg (1 mg/mL)
Trial: 16113431
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICSs) such as fluticasone
Trial: 8036221
Drug: Multimodality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality treatment using oliphenum, prednisolone or their combination
Trial: 28843241
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with intravenous sodium glycerophosphate (Glycophos) 1.5 mmol/kg/day
Trial: 21129944
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 μg/nasal cavity twice daily
Trial: 19001519
Drug: Individualized GH
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized GH dose (17-100 microg/kg.d)
Trial: 19001519
Drug: Standard GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GH dose (43 microg/kg.d)
Trial: 16730488
Drug: Valdecoxib, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib, 40 mg, once a day for 5 days
Trial: 10904459
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d
Trial: 3521187
Drug: Single-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug chemotherapy
Trial: 22829267
Drug: MSC (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC (4 × 10(7) /injection) via intra-arterial and intravenous routes
Trial: 18206738
Drug: No ICD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ICD therapy (control group)
Trial: 15999885
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel (15 mL of 2% lidocaine administered intrarectally ten minutes before biopsy)
Trial: 15999885
Drug: Lidocaine periprostatic
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine periprostatic infiltration (10 mL of 1% lidocaine given under ultrasound guidance in two periprostatic injections of 5 mL, four minutes before biopsy)
Trial: 12450598
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (half-dose reteplase and full-dose abciximab)
Trial: 12450598
Drug: Reteplase (standard-dose)
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase (standard-dose)
Trial: 7574130
Drug: Subcutaneous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous epinephrine and nebulized metaproterenol
Trial: 2183055
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of continuous intravenous heparin with warfarin sodium begun on the first day
Trial: 2183055
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of intravenous heparin with warfarin sodium begun on the fifth day
Trial: 2183055
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of continuous intravenous heparin
Trial: 2183055
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of intravenous heparin
Trial: 6104634
Drug: GYKI-41099 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GYKI-41099 2.5, 5 and 10 mg
Trial: 6104634
Drug: Propranolol 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 10, 20 and 40 mg
Trial: 6104634
Drug: GYKI-41099 5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GYKI-41099 5-15 mg daily for 2 months
Trial: 19169239
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 0.04 ml/1 mg
Trial: 19169239
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy plus intravitreal triamcinolone (PDT+IVTA) 0.1 ml/4 mg
Trial: 11345366
Drug: Bradykinin (BK)
RxNorm normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in ACE inhibitor group
Trial: 11345366
Drug: Bradykinin (BK)
RxNorm normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, 2.0 microg/min) in non-ACE inhibitor group
Trial: 11345366
Drug: Papaverine (PA)
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine (PA) (12 mg)
Trial: 8989000
Drug: Small-dose hypobaric
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose hypobaric solution of 1% lidocaine 25 mg with fentanyl 25 micrograms
Trial: 8989000
Drug: Conventional-dose hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose hyperbaric solution of 5% lidocaine 75 mg
Trial: 3315687
Drug: Theophylline preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline preparation (18 mg/kg per day at 2000 hours)
Trial: 31197364
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish containing 1.5% ammonium fluoride applied every sixth week during orthodontic treatment.
Trial: 31197364
Drug: Placebo varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo varnish without fluoride applied every sixth week during orthodontic treatment.
Trial: 24166941
Drug: Non‐specific neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐specific neurocognitive therapy (NNT)
Trial: 19827964
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine solution (2 per thousand)